New Order Issued in Federal Incretin Mimetic Litigation, Where Hundreds of Byetta Lawsuits and other Diabetes Drug Claims Have Been Filed

Share Article

The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin mimetic diabetes medications.

Our Firm continues to hear from individuals who were allegedly injured by Byetta and other medications.

Past News Releases

A federal multidistrict litigation involving Byetta lawsuits (http://www.byettalawsuit2013.com/), as well as claims over similar Type 2 diabetes medications is continuing to move forward in the Southern District of California, Bernstein Liebhard LLP reports.

According to court documents filed on November 25th, a stay on the consideration of jurisdictional issues in several cases in the proceeding has been lifted, after being ordered a month earlier by the Court. These and other diabetes drug lawsuits now pending in California federal court similarly allege pancreatic cancer, pancreatitis and thyroid cancer caused by a class of diabetes drugs referred to as incretin mimetics, which include but are not limited to Byetta, Januvia, and Victoza. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)

“We are pleased to see continued progress in the federal incretin mimetics litigation, as our Firm continues to hear from individuals who were allegedly injured by Byetta and other medications,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including Byetta. The Firm is actively filing lawsuits on behalf of individuals who were allegedly harmed by the medication.

Byetta Lawsuits
As per court documents updated in November, a total of 540 diabetes drug lawsuits have now been filed in the incretin mimetic litigation underway in the Southern District of California. Plaintiffs in these cases, many of which involving Byetta, allege that the manufacturers of these products failed to properly warn about the serious side effects they may cause. Claims in this proceeding have increased substantially since the U.S. Food and Drug Administration (FDA) issued a public warning about incretin mimetics in March 2013, in which they alerted the public of a previously unpublished study that found precancerous changes in the pancreas’ of individuals who had been using the diabetes drugs. The alleged link had not been confirmed at the time, the federal agency said, but its review was ongoing.

In addition to Byetta lawsuits filed in federal court, recent records show several cases centralized in a state-level proceeding established in California Superior Court. (In re: Byetta Cases, JCCP No. 4574) The product’s manufacturer, AstraZeneca, acknowledged in July that more than 80 Byetta lawsuits had been settled.*

Individuals who developed pancreatitis, pancreatic cancer or thyroid cancer after taking Byetta or another incretin mimetic may be entitled to compensation for injury-related damages. Learn more about the possible link between Byetta and pancreatic cancer when you visit Bernstein Liebhard LLP’s website. For a free legal review, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092